Tessera introduces new genome engineering strategy

By The Science Advisory Board staff writers

July 7, 2020 -- Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing technology to cure diseases.

The Gene Writing platform addresses key limitations of gene therapy and gene editing techniques. The new technology can efficiently insert genes and exons, introduce small insertions or deletions, or change single or multiple DNA base pairs. This could help fix errors associated with monogenic disorders (caused by variation in a single gene) or allow precise gene regulation in other complex diseases (neurodegenerative diseases, autoimmune disorders, and metabolic diseases).

The technology was developed by a collaboration of Massachusetts Institute of Technology researchers and scientists at Flagship Labs. Tessera was founded in 2018 to create a platform that could design, make, and launch Gene Writing medicines. Mobile genetic elements -- genetic material that can move around within a genome -- are engineered to create the technology. RNA or DNA templates are used to write therapeutic messages into the genome.

The Gene Writing platform helps overcome many of the limitations of previous genetic medicine approaches. Specifically, it is able to do the following:

  • Make alterations to the genome of somatic cells with minimal reliance upon host DNA repair pathways
  • Permanently add new DNA to dividing cells
  • Write new DNA sequences into the genome by delivering only RNA
  • Allow repeated administration of treatments to dose to effect

Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here